Tuberculosis screening practices and outcomes in an australian dialysis unit

Abstract Background The World Health Organisation (WHO) recommends all dialysis patients undertake routine screening for latent tuberculosis infection (LTBI) in high income countries such as Australia. However, we employ a targeted screening approach in our Australian dialysis unit in line with loca...

Full description

Bibliographic Details
Main Authors: Hannah Wallace, Craig Nelson, Sandra Crikis
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Nephrology
Subjects:
Online Access:https://doi.org/10.1186/s12882-023-03304-0
_version_ 1797577500315877376
author Hannah Wallace
Craig Nelson
Sandra Crikis
author_facet Hannah Wallace
Craig Nelson
Sandra Crikis
author_sort Hannah Wallace
collection DOAJ
description Abstract Background The World Health Organisation (WHO) recommends all dialysis patients undertake routine screening for latent tuberculosis infection (LTBI) in high income countries such as Australia. However, we employ a targeted screening approach in our Australian dialysis unit in line with local and some international guidelines. We analysed our practices to assess the validity of our approach. Methods A retrospective review of new dialysis patients during the period 2012–2018 was undertaken. Patient records were reviewed for basic demographic data, comorbidities, LTBI screening using Quantiferon Gold (QFG), and outcomes, including episodes of active TB, to June 2020. Results 472 patients were included. WHO high risk country of origin patients accounted for 22% (n = 103). 229 patients (48.5%) were screened using QFG. The single main indication for screening was transplantation waitlisting. 34 patients had a positive QFG result. Active tuberculosis developed in two patients during the observation period. Both occurred in the screened cohort, the cases having previously tested negative via QFG at 11 and 16 months, prior to the development of active tuberculosis. No patients in the unscreened cohort developed active tuberculosis during the observation period. WHO high risk country of origin was associated with positive QFG status, odds ratio 10.4 (95% CI 3.3–31.2). Conclusion The data failed to show a benefit from widening of the screening program within our dialysis unit. However, a much larger sample size will be required to confidently assess the impact of the current approach on patient outcomes. Analysis of current screening practices and outcomes across all Australian dialysis services is warranted to assess the risks and benefits of widening the screening practices to include all dialysis patients as recommended by the WHO.
first_indexed 2024-03-10T22:09:12Z
format Article
id doaj.art-4055c8b2e6be4245b0f4a67af4476b67
institution Directory Open Access Journal
issn 1471-2369
language English
last_indexed 2024-03-10T22:09:12Z
publishDate 2023-08-01
publisher BMC
record_format Article
series BMC Nephrology
spelling doaj.art-4055c8b2e6be4245b0f4a67af4476b672023-11-19T12:39:21ZengBMCBMC Nephrology1471-23692023-08-012411710.1186/s12882-023-03304-0Tuberculosis screening practices and outcomes in an australian dialysis unitHannah Wallace0Craig Nelson1Sandra Crikis2Department of Nephrology, Western HealthDepartment of Nephrology, Western HealthDepartment of Nephrology, Western HealthAbstract Background The World Health Organisation (WHO) recommends all dialysis patients undertake routine screening for latent tuberculosis infection (LTBI) in high income countries such as Australia. However, we employ a targeted screening approach in our Australian dialysis unit in line with local and some international guidelines. We analysed our practices to assess the validity of our approach. Methods A retrospective review of new dialysis patients during the period 2012–2018 was undertaken. Patient records were reviewed for basic demographic data, comorbidities, LTBI screening using Quantiferon Gold (QFG), and outcomes, including episodes of active TB, to June 2020. Results 472 patients were included. WHO high risk country of origin patients accounted for 22% (n = 103). 229 patients (48.5%) were screened using QFG. The single main indication for screening was transplantation waitlisting. 34 patients had a positive QFG result. Active tuberculosis developed in two patients during the observation period. Both occurred in the screened cohort, the cases having previously tested negative via QFG at 11 and 16 months, prior to the development of active tuberculosis. No patients in the unscreened cohort developed active tuberculosis during the observation period. WHO high risk country of origin was associated with positive QFG status, odds ratio 10.4 (95% CI 3.3–31.2). Conclusion The data failed to show a benefit from widening of the screening program within our dialysis unit. However, a much larger sample size will be required to confidently assess the impact of the current approach on patient outcomes. Analysis of current screening practices and outcomes across all Australian dialysis services is warranted to assess the risks and benefits of widening the screening practices to include all dialysis patients as recommended by the WHO.https://doi.org/10.1186/s12882-023-03304-0Latent tuberculosis infectionDialysisActive tuberculosisQuantiferon Gold screening
spellingShingle Hannah Wallace
Craig Nelson
Sandra Crikis
Tuberculosis screening practices and outcomes in an australian dialysis unit
BMC Nephrology
Latent tuberculosis infection
Dialysis
Active tuberculosis
Quantiferon Gold screening
title Tuberculosis screening practices and outcomes in an australian dialysis unit
title_full Tuberculosis screening practices and outcomes in an australian dialysis unit
title_fullStr Tuberculosis screening practices and outcomes in an australian dialysis unit
title_full_unstemmed Tuberculosis screening practices and outcomes in an australian dialysis unit
title_short Tuberculosis screening practices and outcomes in an australian dialysis unit
title_sort tuberculosis screening practices and outcomes in an australian dialysis unit
topic Latent tuberculosis infection
Dialysis
Active tuberculosis
Quantiferon Gold screening
url https://doi.org/10.1186/s12882-023-03304-0
work_keys_str_mv AT hannahwallace tuberculosisscreeningpracticesandoutcomesinanaustraliandialysisunit
AT craignelson tuberculosisscreeningpracticesandoutcomesinanaustraliandialysisunit
AT sandracrikis tuberculosisscreeningpracticesandoutcomesinanaustraliandialysisunit